Embryo Testing (PGT)
PGT-A
Screens embryos for the right number of chromosomes before transfer.
Screens all 24 chromosomes for whole-chromosome aneuploidy to identify euploid embryos.
- Specimen
- Trophectoderm biopsy (day 5-6 blastocyst)
- Methodology
- Next-generation sequencing (24-chromosome)
- Category
- Embryo Testing (PGT)
Pricing is available through your BioBloom portal or on request.
This test requires genetic counselling and written consent — your clinic will confirm this at ordering.
How it works
- 1
Order
Place the order through the BioBloom portal.
- 2
Sample
Collect the sample — Trophectoderm biopsy (day 5-6 blastocyst).
- 3
Analysis
Laboratory analysis — Next-generation sequencing (24-chromosome).
- 4
Report
Secure report delivered to your clinic through the portal.
What’s in the report
Euploid/aneuploid call per embryo with chromosome copy-number and any mosaicism flag.
Research & evidence
PGT-M/SR established; PGT-A used selectivelyPGT & embryo testing
PGT-M and PGT-SR are well-established for monogenic disease and structural rearrangements. PGT-A and non-invasive PGT-A are best used selectively, with the clearest signal in older patients per transfer.
Limitations: Randomised trials have not shown PGT-A to improve cumulative live birth in unselected patients: it selects between existing embryos rather than improving them. niPGT-A from spent culture medium is investigational, and its concordance with trophectoderm biopsy varies between laboratories.
Read the researchMore in Embryo Testing (PGT)
PGT-SR
For carriers of chromosome rearrangements; finds the balanced embryos.
PGT-M
Tests embryos for a specific inherited disease that runs in the family.
Secure Select (niPGT-A)
Chromosome screening from the embryo’s culture fluid — used alongside, not instead of, biopsy PGT-A.
